Home > Result Summaries: Compounds > Varicella Vaccine Result Summaries: Varicella Vaccine GSKStudy ID Phase Title Summary (Download) 100388 phase 3 Study in Healthy Children (<2 Years) to Evaluate the Safety & Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) & of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine (0 citation(s)) 101501 phase 1 An exploratory, open, randomized, phase I-II study to evaluate the safety and the immune responses to VZV induced by an investigational vaccination regimen or a live attenuated OKA VZV vaccine in adult subjects aged 18-30 years and in adult subjects aged 50-70 years (1 citation(s)) 109705 phase 2 Study of two formulations of GSK Biologicals' varicella vaccine given as a 2-dose course in the second year of life (0 citation(s)) 109737 phase 4 The effectiveness of varicella vaccination in children in Germany (2 citation(s)) 208133/161 Phase 4 A controlled clinical study to assess the immunogenicity and reactogenicity of SmithKline Beecham Biologicalsvaricella vaccine in children aged between 1 and 12 years with a known history of neurodermatitis.SmithKline Beecham Biologicals is currently GlaxoSmithKline Biologicals. (3 citation(s)) 208133/178 Phase 2 The immunogenicity and safety of GSK Biologicals’ varicella vaccine (VARILRIXTM), given as a primary vaccination at 4.5 M and 6.5 M post-transplantation, in autologous stem cell/bone marrow transplantation recipients aged 18 years and older. (0 citation(s)) 763310/001 Phase 1/Phase 2 A phase I/II trial of an investigational vaccination regimen in infants. (0 citation(s))
